Phase 3 trial results have been recently published for the first pills and they are quite promising
9 The peer companies and their ratios noted in the figure include Abbvie(1.25), Amgen(1.32), AstraZeneca(0.36), Biogen(0.71), Bristol-Myers(0.86), Eli Lilly(0.43), Gilead(0.70), GSK(0.54), JNJ(0.76), Merck(0.38), Novartis(1.25), Novo Nordisk(1.41), Pfizer(0.71), Roche(0.86), and Sanofi(0.57) 10 Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
Most telehealth clinics will not tell you who touches your medication, so this level of openness stands out
PT, preferred term
A recent KFF poll of all adults (insured and uninsured) showed that insurance covered all of the cost for GLP-1 agonists for 1 out of 4 patients using them according to self-reported responses, but over half (54%) of adults taking these drugs had difficulty paying for them
Tirzepatide May Be Right for You If: You have overweight or obesity with significant visceral (belly) fat You struggle with severe insulin resistance or type 2 diabetes Your weight gain is linked to hormonal or metabolic imbalance (PCOS, metabolic syndrome) You have tried Semaglutide or similar treatments without satisfactory results You experience plateaus despite diet and exercise You need stronger appetite suppression plus metabolic fat reduction Best for: Patients who need more powerful, dual-action support for stubborn fat, blood-sugar control, and faster metabolic improvement